{"keywords": [{"value": "Theranos Inc", "rank": "1", "is_major": "Y", "name": "organizations"}, {"value": "Tests (Medical)", "rank": "2", "is_major": "Y", "name": "subject"}, {"value": "Blood", "rank": "3", "is_major": "Y", "name": "subject"}, {"value": "Food and Drug Administration", "rank": "4", "is_major": "Y", "name": "organizations"}, {"value": "Start-ups", "rank": "5", "is_major": "N", "name": "subject"}, {"value": "Holmes, Elizabeth (1984- )", "rank": "6", "is_major": "N", "name": "persons"}, {"value": "Boies, David", "rank": "7", "is_major": "N", "name": "persons"}, {"value": "Laboratories and Scientific Equipment", "rank": "8", "is_major": "N", "name": "subject"}, {"value": "Regulation and Deregulation of Industry", "rank": "9", "is_major": "N", "name": "subject"}], "headline": {"print_headline": "Blood Test Start-Up Faces F.D.A. Scrutiny ", "main": "Theranos, a Blood Test Start-Up, Faces F.D.A. Scrutiny"}, "byline": {"original": "By ANDREW POLLACK and REED ABELSON", "person": [{"rank": 1, "role": "reported", "organization": "", "lastname": "POLLACK", "firstname": "Andrew"}, {"rank": 2, "role": "reported", "organization": "", "lastname": "ABELSON", "firstname": "Reed"}]}, "web_url": "http://www.nytimes.com/2015/10/17/business/theranos-a-blood-test-start-up-faces-fda-scrutiny.html", "source": "The New York Times", "subsection_name": null, "slideshow_credits": null, "type_of_material": "News", "_id": "56219d1438f0d875be24df1f", "multimedia": [{"height": 126, "subtype": "wide", "legacy": {"widewidth": "190", "wideheight": "126", "wide": "images/2015/10/17/business/17THERANOS/17THERANOS-thumbWide.jpg"}, "type": "image", "width": 190, "url": "images/2015/10/17/business/17THERANOS/17THERANOS-thumbWide.jpg"}, {"height": 400, "subtype": "xlarge", "legacy": {"xlargeheight": "400", "xlargewidth": "600", "xlarge": "images/2015/10/17/business/17THERANOS/17THERANOS-articleLarge.jpg"}, "type": "image", "width": 600, "url": "images/2015/10/17/business/17THERANOS/17THERANOS-articleLarge.jpg"}, {"height": 75, "subtype": "thumbnail", "legacy": {"thumbnailwidth": "75", "thumbnailheight": "75", "thumbnail": "images/2015/10/17/business/17THERANOS/17THERANOS-thumbStandard.jpg"}, "type": "image", "width": 75, "url": "images/2015/10/17/business/17THERANOS/17THERANOS-thumbStandard.jpg"}], "pub_date": "2015-10-17T00:00:00Z", "print_page": "1", "section_name": "Business Day", "word_count": "805", "blog": [], "news_desk": "Business", "snippet": "In response to questions raised by the Food and Drug Administration, the medical testing start-up has temporarily stopped its signature practice of collecting tiny blood samples from finger pricks.", "document_type": "article", "abstract": "Blood testing start-up Theranos temporarily stops its trademark practice of collecting small blood samples from finger pricks; firm faces scrutiny by Food and Drug Administration over its data, as reliability of its test results have been questioned.", "lead_paragraph": "In response to questions raised by the Food and Drug Administration, the medical testing start-up has temporarily stopped its signature practice of collecting tiny blood samples from finger pricks."}